Completed PHASE2 INTERVENTIONAL 3-arm NCT02545959

Intrathecal Rituximab in Progressive Multiple Sclerosis (EFFRITE)

Sponsor: Centre Hospitalier de PAU

Conditions Multiple Sclerosis, Chronic Progressive Nervous System Diseases

Interventions Rituximab IT Rituximab IV methylprednisolone IV

Updated 8 times since 2017 Last updated: Oct 2, 2019 Started: Nov 30, 2015 Primary completion: Feb 22, 2019 Completion: Sep 2, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Multiple Sclerosis, Chronic Progressive and Nervous System Diseases and is currently completed. Centre Hospitalier de PAU leads this study, which shows 8 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Nov 2019 — Jan 2021 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
May 2019 — Nov 2019 [monthly]

Active Not Recruiting PHASE2

Status: Unknown Status → Active Not Recruiting

▶ Show 3 earlier versions

Jun 2018 — May 2019 [monthly]

Unknown Status PHASE2
Oct 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2017 — Oct 2017 [monthly]

Recruiting PHASE2

First recorded

Nov 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Centre Hospitalier de PAU
University Hospital, Bordeaux

Data source: Centre Hospitalier de PAU

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pau, France